JACC: Case Reports (Jan 2021)

First Follow-Up of Cardiac Amyloidosis Treated by Tafamidis, Evaluated by Absolute Quantification in Bone Scintigraphy

  • Dimitri Bellevre, MD,
  • Alban Bailliez, MD, PhD,
  • Sylvestre Maréchaux, MD, PhD,
  • Alain Manrique, MD, PhD,
  • Frédéric Mouquet, MD, PhD

Journal volume & issue
Vol. 3, no. 1
pp. 133 – 135

Abstract

Read online

Assessment of absolute myocardial hydroxydimethylene diphosphonate–technetium-99m uptake using standardized uptake value with a single-photon emission computed tomography–computed tomography cadmium zinc telluride camera (Discovery NM/CT 670CZT, GE Healthcare, Chicago, Illinois) in a patient with cardiac transthyretin-related amyloidosis treated with tafamidis showed a decrease in hydroxydimethylene diphosphonate cardiac uptake. This imaging technique should be helpful in monitoring therapy and evaluating prognosis. (Level of Difficulty: Intermediate.)

Keywords